Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
500 CHF | +194.12% | -.--% | -.--% |
04/06 | Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab | |
04/06 | J&J: successful trial for Carvykti in multiple myeloma | CF |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 3.95 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 36TCr | - | ||
+42.83% | 75TCr | C+ | ||
+34.11% | 61TCr | B | ||
+18.06% | 33TCr | B- | ||
+4.63% | 29TCr | C+ | ||
+17.02% | 25TCr | B+ | ||
+9.26% | 21TCr | B- | ||
-4.21% | 21TCr | A+ | ||
+2.43% | 17TCr | C+ | ||
+6.67% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson